DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company that entered the public markets through a merger with Constellation Alpha Capital Corp, a blank-check vehicle sponsored by Constellation Alpha Capital, LLC, with the transaction closing in 2019. The company operates in the genomic diagnostics and dermatology sector, having developed a non-invasive adhesive skin genomics platform aimed at improving early melanoma detection. DermTech filed an 8-K current report with the SEC on May 17, 2024, reflecting a notable corporate development during a period of pronounced operational and financial pressure for the post-merger company. Sign up on SpacDesk for DermTech's complete filing history, deal terms, and post-merger performance data alongside the full SPAC universe.